Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Multicentre Open Label Study Evaluating the Efficacy and Safety of Liposomal Doxorubicin, Trastuzumab, Docetaxel as First-line Treatment of Patients With HER2 Positive Metastatic Breast Cancer

NCT00377780 is registered in ClinicalTrials.gov with Laurence J.C. van Warmerdam as lead sponsor.

NCT NCT00377780
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00377780 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Multicentre Open Label Study Evaluating the Efficacy and Safety of Liposomal Doxorubicin, Trastuzumab, Docetaxel as First-line Treatment of Patients With HER2 Positive Metastatic Breast Cancer
Lead sponsor
Laurence J.C. van Warmerdam
Phase
Phase 2
Overall status
Terminated
Start date
August 31, 2006
Completion date
August 31, 2015
Enrollment
60 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, neoplasm metastasis